Perfused human organs versus Mary Shelley's Frankenstein

Area of Science:

• Translational medicine
• Pharmacology
• Organ-on-a-chip technology

Background:

• Pre-clinical drug testing faces high failure rates due to poor translation from in vitro to in vivo models.
• Current bench-to-bedside (N2B) translational medicine lacks sufficient human physiological relevance.
• There is a critical need for advanced pre-clinical models that better mimic human physiology.

Discussion:

• The Ex Vivo Metrics system offers a novel approach by utilizing perfused human organs for drug screening.
• This technology allows for the assessment of both drug efficacy and potential toxicity in a human-relevant context.
• Perfused human organs in a controlled environment represent a significant advancement in pre-clinical research.

Key Insights:

• Ex Vivo Metrics technology provides a more accurate prediction of drug responses compared to traditional methods.
• It addresses the limitations of current in vitro and animal models in predicting human outcomes.
• This system facilitates a more efficient and reliable drug development pipeline.

Outlook:

• Further development and validation of the Ex Vivo Metrics system are crucial for its widespread adoption.
• This technology has the potential to significantly reduce drug development costs and timelines.
• Perfused human organ models could revolutionize pre-clinical drug discovery and personalized medicine.